

## INDEPENDENT AUDITOR'S REPORT

To,  
The Partners of  
Zullinc Healthcare LLP  
Ahmedabad

Report on the Audit of the Financial Statements

### Opinion

1. We have audited the accompanying financial statements of Zullinc Healthcare LLP ("the LLP"), which comprise the Balance Sheet as at March 31, 2019, and the Statement of Profit and Loss account, and statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanation given to us, the aforesaid financial statements are prepared, in all material respects, in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India (ICAI) and in accordance with the accounting principles generally accepted in India.

### Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) issued by ICAI. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the LLP in accordance with the ethical requirements that are relevant to our audit of the financial statements in India, and we have fulfilled our other responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Responsibilities of Designated Partners for the financial statements

4. Designated Partners are responsible for the preparation of the financial statements in accordance with the with the aforesaid Accounting Standards and in accordance with the accounting principles generally accepted in India, and for such internal control as designated partners determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
5. In preparing the financial statements, designated partners are responsible for assessing the LLP's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and

using the going concern basis of accounting unless designated partners either intends to liquidate the LLP or to cease operations, or has no realistic alternative but to do so.

Those Designated Partners are responsible for overseeing the LLP's financial reporting process.

#### Auditor's Responsibilities for the Audit of the financial statements

6. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

#### Other Matter

7. The comparative financial information of the LLP for the year ended March 31, 2018 prepared in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India (ICAI) and in accordance with the accounting principles generally accepted in India, included in these financial statements have been audited by the predecessor auditor. The report of the predecessor auditor on the comparative financial information dated April, 25, 2018 expressed unmodified opinion.

Our opinion on the financial statements is not modified in respect of this matter.

For, K. P. Sompura & Co.  
Chartered Accountants,  
[Firm Regd. No. 131641W]

Place: Ahmedabad  
Date: 29/05/2019

(K. P. Sompura)  
Partner  
[M. No. 045155]

## Zullinc Healthcare LLP

### STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019

Particulars	Note No.	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
I Revenue from operations	16	3,48,74,513	30,58,97,838
II Other Income	17	1,60,302	99,138
III Total Income (I + II)		3,50,34,815	30,59,96,977
IV EXPENSES			
(a) Cost of materials consumed			
(b) Purchases of stock-in-trade	18	2,71,74,832	30,46,60,541
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress		Nil	Nil
(d) Excise duty		Nil	Nil
(e) Employee benefit expense	19	12,00,000	Nil
(f) Finance costs	20	13,628	14,753
(g) Depreciation and amortisation expense		Nil	Nil
(h) Other expenses	21	51,47,492	2,66,993
Total Expenses		3,35,35,953	30,49,42,287
V Profit before tax (III- IV)		14,98,862	10,54,690
VI Tax Expense			
(1) Current tax	22	4,16,814	2,27,809
(2) Deferred tax Liability / (assets)		Nil	Nil
Total tax expense		4,16,814	2,27,809
VII Profit after tax from continuing operations (V - VI)		10,82,048	8,26,881
VIII Profit for the period (VII)		10,82,048	8,26,881
IX Other Comprehensive Income			
A (i) Items that will not be reclassified to profit or loss			
(a) Remeasurements of the defined benefit plans		Nil	Nil
(b) Equity instruments through other comprehensive income		Nil	Nil
(ii) Income tax relating to items that will not be reclassified to profit or loss		Nil	Nil
X Total Other Comprehensive Income		Nil	Nil
XI Total comprehensive income for the period (VIII+IX)		10,82,048	8,26,881

As per our report of even date attached herewith.

For, K. P. Sompura & Co.  
Chartered Accountants  
(Firm Regd.No. 131641W)

For and on behalf of the partners of  
Zullinc Healthcare LLP

Mahendra G. Patel  
(Designated Partners)

[K.P.Sompura]  
Proprietor  
(M.No.045155)  
Place : Ahmedabad  
Date : 29.05.2019

Hasmukhbhai I. Patel  
(Designated Partners)

Place : Ahmedabad  
Date : 29.05.2019

## Zullinc Healthcare LLP

BALANCE SHEET AS AT MARCH 31, 2019				
Particulars		Note No.	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
A	<b>ASSETS</b>			
1	Non-current assets			
	(a) Property, Plant and Equipment		Nil	Nil
	(b) Financial Assets			
	(i) Investments	5	Nil	15,000
	(ii) Loans		Nil	Nil
	(c) Other non-current assets		Nil	Nil
	Total Non - Current Assets		Nil	15,000
2	Current assets			
	(a) Inventories		Nil	Nil
	(b) Financial Assets			
	(i) Investments			
	(ii) Trade receivables	6	15,57,49,705	14,44,88,028
	(iii) Cash and cash equivalents	7	12,06,612	10,00,492
	(iv) Other Bank balances		Nil	Nil
	(v) Loans		Nil	Nil
	(vi) Other Financial assets	8	1,10,414	Nil
	(c) Current Tax Assets (Net)	9	1,86,959	Nil
	(d) Other current assets	10	45,67,079	44,82,890
	Total Current Assets		16,18,20,769	14,99,71,410
	Total Assets (1+2)		16,18,20,769	14,99,86,410
B	<b>EQUITY AND LIABILITIES</b>			
1	Equity			
	(a) Equity share capital	11	5,00,000	5,00,000
	(b) Other Equity	12	Nil	Nil
	Total equity		5,00,000	5,00,000
	<b>LIABILITIES</b>			
2	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings		Nil	Nil
	(ii) Other financial liabilities		Nil	Nil
	(b) Deferred tax liabilities (Net)		Nil	Nil
	Total Non - Current Liabilities		Nil	Nil
3	Current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings			
	(ii) Trade payables	13	14,43,09,854	13,98,41,066
	(iii) Other financial liabilities	14	1,65,94,101	94,70,334
	(b) Other current liabilities		Nil	Nil
	(c) Current Tax Liabilities (Net)	15	4,16,814	1,75,010
	Total Current Liabilities		16,13,20,769	14,94,86,410
	Total Equity and Liabilities (1+2+3)		16,18,20,769	14,99,86,410
	Summary of Significant Accounting Policies	4		
<p>As per our report of even date attached herewith                      For, K. P. Sompura &amp; Co.                      Chartered Accountants                      (Firm Regd.No. 131641W)</p> <p>[K.P.Sompura]                      Proprietor                      (M.No.045155)</p> <p>Place : Ahmedabad                      Date : 29.05.2019</p>		<p>For and on behalf of the partners of                      Zullinc Healthcare LLP</p> <p style="text-align: center;">Mahendra G. Patel                      (Designated Partners)</p> <p style="text-align: center;">Hasmukhbhai I. Patel                      (Designated Partners)</p> <p style="text-align: center;">Place : Ahmedabad                      Date : 29.05.2019</p>		

## Zullinc Healthcare LLP

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2019		
Particulars	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
Cash flow from operating activities		
Profit before tax	14,98,862	10,54,690
Adjustments for :		
Finance costs	13,628	14,753
<b>Operating profit before working capital changes</b>	<b>15,12,490</b>	<b>10,69,443</b>
Changes in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(1,12,61,677)	(23,29,168)
(Increase)/Decrease in loans (current financial asset)	(1,10,414)	7,503
(Increase)/Decrease in other current assets	(84,189)	2,02,395
Increase/(Decrease) in trade payable	44,68,788	16,61,152
Increase/(Decrease) in other current financial liabilities	60,41,720	3,851
Increase/(Decrease) in other current liabilities		
Cash flow generated from operations	(9,45,772)	(4,54,267)
Direct taxes paid (net)	(3,61,970)	(4,89,820)
<b>NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES (A)</b>	<b>2,04,748</b>	<b>1,25,356</b>
Cash flows from investing activities		
Purchase of property, plant and equipments	Nil	Nil
Decrease in Non Current Investment	15,000	Nil
<b>NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES (B)</b>	<b>15,000</b>	<b>Nil</b>
Cash flows from financing activities		
Finance costs paid	(13,628)	(14,753)
Repayment of short-term borrowings	Nil	Nil
Repayment of long-term borrowings	Nil	Nil
<b>NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES (C)</b>	<b>(13,628)</b>	<b>(14,753)</b>
<b>NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)</b>	<b>2,06,120</b>	<b>1,10,603</b>
Cash and cash equivalents at the beginning of the year	10,00,492	8,89,890
Cash and cash equivalents at the end of the year	12,06,612	10,00,492
Notes:		
(i). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.		
(ii). Previous Periods' / Years' figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.		
(iii). Components of cash and cash equivalents at each balance sheet:		
Particulars	As at March 31, 2019Rs.	As at March 31, 2018Rs.
Cash on hand	12,06,612	10,00,492
Balances with Bank - In Current Account	Nil	Nil
<b>Total Cash and cash equivalents (Refer Note 7)</b>	<b>12,06,612</b>	<b>10,00,492</b>
See accompanying notes forming part of the Financial Statements		
As Per our report of even date attached herewith		
For, K. P. Sompura & Co.		
Chartered Accountants		
(Firm Regd.No. 131641W)		
For and on behalf of the partners of Zullinc Healthcare LLP		
Mahendra G. Patel (Designated Partners)		
[K.P.Sompura]		
Proprietor		
(M.No.045155)		
Place : Ahmedabad		
Date : 29.05.2019		
Hasmukhbhai I. Patel (Designated Partners)		
Place : Ahmedabad		
Date : 29.05.2019		

**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED ON MARCH 31, 2019**

**Equity Share Capital**

Particulars	Note No.	Amount Rs.
Balance as on 1st April, 2017	11	5,00,000
Changes during the year		-
Balance as on 31st March, 2018	11	5,00,000
Changes during the year		-
Balance as on 31st March, 2019	11	5,00,000

**Other Equity**

Amount in Rs.

Particulars	Note No.	Reserves and Surplus		Total
		Retained Earnings		
		Profit and Loss	Other Comprehensive Income	
Balance as at 1st April, 2017	12	Nil	Nil	Nil
Profit for the year		8,26,881	Nil	8,26,881
Less : Transfer to Partner's Capital Account		8,26,881	Nil	8,26,881
Balance as at 31st March, 2018	12	Nil	Nil	Nil
Profit for the year		10,82,048	Nil	10,82,048
Less : Transfer to Partner's Capital Account		10,82,048	Nil	10,82,048
Balance as at 31st March, 2019	12	Nil	Nil	Nil

As per our report of even date attached herewith.  
 For, K. P. Sompura & Co.  
 Chartered Accountants  
 (Firm Regd.No. 131641W)

For and on behalf of the partners of  
 For, Zullinc Healthcare LLP

Mahendra G. Patel  
 (Designated Partners)

[K.P.Sompura]  
 Proprietor  
 (M.No.045155)  
 Place : Ahmedabad  
 Date : 29.05.2019

Hasmukhbhai I. Patel  
 (Designated Partners)  
 Place : Ahmedabad  
 Date : 29.05.2019

## Notes to financial statement for the year ended March 31, 2019

### 1. Corporate information:

Zullinc Healthcare LLP (Formally known as Zullinc Healthcare Limited) is a Limited Liability Partnership, Registered under the Liability Partnership Act, 2008. The Conversion of said LLP into LLP was carried on 1st February, 2016.

These financial statements are presented in Indian rupee with figures rounded off to nearest rupee except otherwise indicated and same were approved by board of the Company in their meeting held on May 29, 2019.

### 2. Statement of compliance:

The financial statements have been prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended read with Section 133 of the Companies Act, 2013.

The current financial statements comprising of Balance Sheet, Statement of Profit and Loss, Statement of Changes in Equity and Statement of Cash Flows as at March 31, 2019 have been prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The accounting policies are applied consistently to all the periods presented in the financial statements.

### 3. Basis of preparation:

The financial statements have been prepared on accrual basis of accounting under historical cost convention in accordance with generally accepted accounting principles in India and the relevant provisions of the Companies Act, 2013 including Indian Accounting Standards notified there under, except for the following where the fair valuation have been carried out in accordance with the requirements of respective Ind AS:

### 4. Summary of significant accounting policies:

#### i) Use of estimates:

The preparation of the financial statements in conformity with Ind AS requires the Management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgements and the use of assumptions in financial statements have been specified in Note 2(ii) below. Accounting estimates could change from period to period. Actual results could differ from estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in financial statements in the period in which the changes are made and, if material, their effects are disclosed in these notes to the individual financial statements

Critical Accounting Estimates and Judgement used in application of Accounting Policies are specified here-in-after:

Key source of estimation of uncertainty at the date of the financial statements, which may cause a material adjustment to the carrying amounts of assets and liabilities in coming financial years are specified here-in-after:

#### a. Income Taxes

Significant judgements are involved in determining the provision for Income Taxes, including amount expected to be paid / recovered for uncertain tax positions. (Also refer Note 9 and 14)

#### b. Other estimates

The preparation of financial statements involves estimates and assumptions that affect the reported amount of assets, liabilities, disclosure of contingent liabilities at the date of financial statements and the reported amount of revenues and expenses for the reporting period. Specifically, the Company estimates the probability of collection of accounts receivable by analyzing historical payment patterns, customer concentrations, customer credit-worthiness and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.

#### ii) income recognition:

##### Revenue from Contracts with Customers

Effective 1st April, 2018, the Company has adopted Ind AS 115 - Revenue from Contracts with Customers (Ind AS 115, the standard) retrospectively with the cumulative effect of applying this standard recognised at the date of initial application. The adoption of this standard did not have any material impact on the financial statements.

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

The revenue towards satisfaction of performance is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligations. The transaction price of goods sold and service rendered is net of variable consideration on account of various discounts offered by the company as part of contract. These variable consideration is estimated based on the expected value of outflow. Revenue (net of variable consideration) is recognised only to the extent that it is highly probable that amount will not be subject to significant reversal when uncertainty relating to its recognition resolved.

##### Sale of Product and Services

The company Trading Pharmaceuticals Products. The performance obligation in case of sale of product and services is satisfied at a point in time i.e. when the material is shipped to the customer or on delivery to the customers as may be specified in the contract. The time taken from entering into order and sale is less than 12 months and the normal credit period offered to customers is also less than 12 months. The company offers trade Discount, Quantity Discount, cash Discount, Discount for Shortage or quality issue discount which are factored while determining transaction price. Revenue is recognised such that significant reversal is not highly probable. The reconciliation between the contract price and revenue recognised is given in note 14.

##### Interest income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis by reference to the principal amount outstanding and at the effective interest rate. Effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

##### Other Operating revenue

Export entitlements are recognized when the right to receive the credits as per the terms of the scheme is established in respect of exports made by the company and when there is no significant uncertainty in receiving the same.

##### Insurance Claim:

Claims receivable on account of Insurance are accounted for to the extent the Company is reasonably certain of their ultimate collection.



iii) Cash and cash equivalents

Cash comprises cash on hand. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

Notes to financial statement for the year ended March 31, 2019

Notes to financial statement for the year ended March 31, 2019			
5	<u>Non-current Investments</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Investments in government securities at amortised cost (Unquoted)		
	National Saving Certificate	Nil	15,000
	Total	Nil	15,000
	Aggregate amount of unquoted investment - At cost	Nil	15,000
6	<u>Trade receivables</u>	As at March 31, 2018 Rs.	As at March 31, 2018 Rs.
	Trade Receivables (Unsecured)		
	Trade Receivable Considered Good - Unsecured	15,57,49,705	14,44,88,028
	Less: Allowance for Expected Credit Loss	Nil	Nil
		15,57,49,705	14,44,88,028
	Trade Receivable Credit Impaired-Unsecured	Nil	Nil
	Less: Allowance for Expected Credit Loss	Nil	Nil
		Nil	Nil
	Total	15,57,49,705	14,44,88,028
	Notes:		
	i. For details of receivables from firms / private companies in which directors of the company are partners / directors, please refer note no.23.		
	ii. The Company had not provided an allowance for impairment of doubtful accounts based on financial condition of the customer, aging of the trade receivable and historical experience of collections from customers. The activity in the allowance for impairment of trade receivables is given below:		
	Allowance Movement for Trade Receivables	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Balance at the beginning of the year	Nil	Nil
Add : Allowance made during the year	Nil	Nil	
Less : Reversal of allowance made during the year	Nil	Nil	
Closing Balance	Nil	Nil	
7	<u>Cash &amp; Cash Equivalents</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Cash on hand	14,306	7,14,306
	Balances with Bank - In Current Account	11,92,306	2,86,186
	Total	12,06,612	10,00,492
8	<u>Other Current Financial Assets</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Loans & Advances	1,10,414	Nil
	Total	1,10,414	Nil
9	<u>Current Tax Assets (Net)</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Advance payment of income tax	8,51,790	Nil
	Less: Provision for income tax	(6,64,831)	Nil
	Total	1,86,959	Nil
10	<u>Other Current Assets</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Deposits	Nil	20,000
	Balances with Statutory Authorities	1,06,907	2,718
	Other Loans & Advances	44,60,172	44,60,172
	Total	45,67,079	44,82,890

11	<u>Partner's Capital Account</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Partner's Capital Account	5,00,000	5,00,000
	Total	5,00,000	5,00,000
12	<u>Other Equity</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	a <u>Retained Earnings</u>		
	Profit and Loss:		
	Balance as per last financial Statement	Nil	Nil
	Add : Profit for the year	10,82,048	8,26,881
	Less: Transfer to Partner's Current Account	10,82,048	8,26,881
	Net Surplus in the statement of profit and loss (i)	Nil	Nil
	Other Comprehensive Income		
	Balance as per last financial Statement	Nil	Nil
	Add: Remeasurement of Defined benefit plans (including deferred tax)	Nil	Nil
Less : Deferred Tax Asset on above	Nil	Nil	
Net Surplus in the statement of other comprehensive income(ii)	Nil	Nil	
Total Retained Earnings (i + ii)	Nil	Nil	
Total			
13	<u>Trade payables</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Payable to Micro and Small Enterprise	Nil	Nil
	Payable to others	14,43,09,854	13,98,41,066
	Total	14,43,09,854	13,98,41,066
i	There were no overdue amounts/interest payable to Micro, Small and Medium Enterprises Development Act, 2006 as at the Balance Sheet date or any time during the year.		
ii	Dues to Micro and Small enterprises have been determined to the extent such parties have been identified on the basis of the information collected by the Management. This has been relied upon by the Auditors.		
14	<u>Other Current Financial Liabilities</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Partner's Current Account	1,03,98,645	93,16,598
	Duties & Taxes	2,15,000	Nil
	Creditor for Expense	59,80,456	1,53,736
	Total	1,65,94,101	94,70,334
15	<u>Current Tax Liabilities (Net)</u>	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Provision For Income tax	4,16,814	1,75,010
	Total	4,16,814	1,75,010
16	<u>Revenue from operation</u>	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Sale of Products:		
	Finished Goods	3,48,74,513	30,58,97,838
	Total	3,48,74,513	30,58,97,838

(a)	<b>Reconciliation of Revenue recognised in the statement of profit and loss with the Contracted price :-</b>		
	Particulars	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Gross Revenue	3,48,74,513	30,58,97,838
	Less: Rebate & Discount etc	3,48,74,513 Nil	30,58,97,838 Nil
	<b>Revenue recognised from Contract with Customers</b>	<b>3,48,74,513</b>	<b>30,58,97,838</b>
(b)	<b>Reconciliation of Revenue from operation with Revenue from contracts with Customers :-</b>		
	Particulars	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Revenue from operation	3,48,74,513	30,58,97,838
	Less: Other Operating Income	Nil	Nil
	<b>Revenue from contracts with Customers</b>	<b>3,48,74,513</b>	<b>30,58,97,838</b>
17	<b>Other Income</b>	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Export Incentive	1,60,302	99,138
	<b>Total</b>	<b>1,60,302</b>	<b>99,138</b>
18	<b>Purchase of Stock in Trade</b>	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Trading Purchase	2,71,74,832	30,46,60,541
	<b>Total .....</b>	<b>2,71,74,832</b>	<b>30,46,60,541</b>
19	<b>Employee Benefit Expenses</b>	Year Ended March 31, 2019	Year Ended March 31, 2018
	Salary	12,00,000	Nil
	<b>Total</b>	<b>12,00,000</b>	<b>Nil</b>
20	<b>Finance Costs</b>	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
	Bank Charges	13,628	14,753
	<b>Total</b>	<b>13,628</b>	<b>14,753</b>
21	<b>Other Expenses</b>	Year Ended March 31, 2018 Rs.	Year Ended March 31, 2018 Rs.
	Professional & Consultancy Charges	Nil	35,000
	Interest on VAT & TDS	Nil	300
	GST Late Filling Fees	2,850	2,880
	Loss on Sale MEIS Licence	Nil	14,304
	Commission Expenses	40,00,000	Nil
	Penalty on Late Filling of TDS Return	1,200	Nil
	Other Administrative Expense	8,61,585	28,759
	<b>Total</b>	<b>48,65,635</b>	<b>81,243</b>
	Discount & Export Air Shipment	2,81,857	1,85,750
	<b>Total</b>	<b>2,81,857</b>	<b>1,85,750</b>
<b>Total</b>	<b>51,47,492</b>	<b>2,66,993</b>	

22	<u>Income tax recognised in profit or loss</u>	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
Current tax:			
In respect of the current year		4,16,814	2,27,809
In respect of the prior year		Nil	Nil
Sub-Total (i)		4,16,814	2,27,809
In respect of the current year		Nil	Nil
Sub-Total (ii)		Nil	Nil
Total (i + ii)		4,16,814	2,27,809

23	Related Parties Disclosures			
	(i) List of related parties:			
	Name of related party	Nature of relationship		
	Lincoln Pharmaceuticals Limited	Holding Company		
	Lincoln Parenteral Limited	Subsidiary of Holding Company		
	(ii) Transactions during the period and balances outstanding with related parties are as under:			
	Transactions with related parties during the year:			
	Name of related party	Nature of Transaction	Year ended March 31, 2019 Rs.	Year ended March 31, 2018 Rs.
	Lincoln Pharmaceuticals Limited	Purchase of goods	25,32,699	16,20,820
		Share of Profit	10,82,048	8,29,128
		Loan Received	Nil	31,00,000
		Loan Settled	Nil	31,00,000
	Lincoln Parenteral Limited	Sales of goods	Nil	31,52,61,148
		Purchase of goods	Nil	Nil
	Balances outstanding at each reporting date:			
	Name of related party	Nature of Amount	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
	Lincoln Parenteral Limited Trade Payable	Payable to others	16,61,152	16,61,152
	Lincoln Pharmaceuticals Ltd Trade Payable	Payable to others	13,37,26,749	13,37,24,863
24	Subsequent Events: Subsequent to Balance Sheet Date, there are no events occurred which require disclosure or adjustments in the financial statements.			
25	Previous Periods' / Years' figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.			
	As per our report of even date attached herewith For, K. P. Sompura & Co. Chartered Accountants (Firm Regd.No. 131641W)		For and on behalf of the partners of Zullinc Healthcare LLP	
	[K.P.Sompura] Proprietor (M.No.045155)		Mahendra G. Patel (Designated Partners)	
	Place : Ahmedabad Date : 29.05.2019		Hasmukhbhai I. Patel (Designated Partners)	
	Place : Ahmedabad Date : 29.05.2019		Place : Ahmedabad Date : 29.05.2019	